Examining the relationship between COVID-19 vaccines and recall rates in breast screening
Keywords:
Breast cancer lymphedema; diagnostic screening programs; COVID-19 vaccine; recall rateAbstract
Background. It has been observed that women vaccinated against coronavirus disease 2019 (COVID-19) may show axillary lymphadenopathy at screening mammogram, which may become suspicious for malignancy, leading to an increased recall rate for further diagnostic evaluations and a higher number of false-positive results, as well as considerable emotional distress for the women involved. Study design. The study aimed to assess the incidence of doubt/positive results in the 1st level mammogram among women who received a COVID-19 vaccine within 4 weeks before mammogram, compared to unvaccinated women. Further aims included the analysis of the distribution of doubt/positive 1st level screening mammogram results according to different women-related and diagnostic work-up-related characteristics, and the evaluation of the incidence of false-positive results observed at the 2nd level. Methods. The cohort study was carried out by retrospectively reviewing electronic data records related to the breast screening program of the Local Health Authority of Bologna in 2021 concerning women between 45 and 74 years old. Excluded were the women outside the age range, with prior breast cancer history, or receiving COVID-19 vaccination more than 4 weeks before the mammogram. Results. A total of 43,856 (mean age 56.6 ± 8.7) women met the study’s inclusion criteria. Among all enrolled women, the recall rate was 5.5% (N=2,394). There were no statistically significant differences in doubt/positive results between vaccinated within 4 weeks before the mammogram and unvaccinated women (5.5% versus 5.4%, p=0.649). However, those who received the Pfizer vaccine showed a significantly higher rate of doubt/positive results. Conclusions. Healthcare professionals’ awareness of vaccine records and educating patients about rare adverse effects can help prevent unnecessary biopsies, interventions, and changes in patient management. Further research is needed to confirm our findings
References
1. European Medicines Agency. Comirnaty. Available from: www.ema.europa.eu/en/medicines/human/EPAR/comirnaty [Last accessed: 2025 Feb 4].
2. European Medicines Agency. Spikevax (previously COVID19 Vaccine Moderna). Available from: www.ema.europa.eu/ en/medicines/human/EPAR/spikevax [Last accessed: 2025 Feb 4].
3. European Medicines Agency. Vaxzevria (previously COVID-19 Vaccine AstraZeneca). Available from: www. ema.europa.eu/en/medicines/human/EPAR/vaxzevria Last accessed: 2025 Feb 4].
4. European Medicines Agency. Jcovden (previously COVID19 Vaccine Janssen). Available from: www.ema.europa.eu/ en/medicines/human/EPAR/jcovden-previously-covid-19vaccine-janssen [Last accessed: 2025 Feb 4].
5. Ministero della Salute, Italy. DM 12/03/2021. Piano strategico vaccinazione COVID. Available from: www. gazzettaufficiale.it/eli/id/2021/03/24/21A01802/sg [Last accessed 2025 Feb 4].
6. Task force COVID-19 del Dipartimento Malattie Infettive e Servizio di Informatica, Istituto Superiore di Sanità. Epidemia COVID-19. Aggiornamento nazionale: 28 dicembre 2021. Available from: www.epicentro.iss.it/coronavirus/ bollettino/Bollettino-sorveglianza-integrata-COVID-19_28dicembre-2021.pdf [Last accessed: 2025 Feb 4].
7. AUSL di Bologna. Report vaccinazioni anti-covid. 2023. Available from: public.flourish.studio/story/761074/ [Last accessed: 2025 Feb. 4].
8. Ahn RW, Mootz AR, Brewington C, Abbara S. Axillary lymphadenopathy after mRNA COVID-19 vaccination. Radiol Cardiothorac Imaging. 2021 Feb 4;3(1):210008. doi: 10.1148/ryct.2021210008. PMID: 33778667; PMCID: PMC7861140.
9. Lehman CD, Lamb LR, D’Alessandro HA. Mitigating the impact of coronavirus disease (COVID-19) vaccinations on patients undergoing breast imaging examinations: a pragmatic approach. AJR Am J Roentgenol. 2021 Sep;217(3):584-6. doi: 10.2214/AJR.21.25688. Epub 2021 Jul 22. PMID: 33617288.
10. Grimm L, Destounis S, Dogan B, Nicholson B, Dontchos B, Sonnenblick E, et al. SBI recommendations for the management of axillary adenopathy in patients with recent COVID19 vaccination. Society of Breast Imaging Patient Care and Delivery Committee (SBI). 2021. Available from: splf.fr/ wp-content/uploads/2021/02/Society-of-breast-imagingRecommendations-for-the-Management-of-Axillary-Adenopathy-in-Patients-with-Recent-COVID-19-VaccinationMis-en-ligne-par-la-Societe-francaise-de-radiologie-le-10 -02-21.pdf [Last accessed: 2025 Feb 4].
11. Lim J, Lee SA, Khil EK, Byeon SJ, Kang HJ, Choi JA. COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: case series with a review of literature. Semin Oncol. 2021 Aug-Dec;48(4-6):283-91. doi: 10.1053/j.seminoncol.2021.10.002. Epub 2021 Oct 26. PMID: 34836672; PMCID: PMC8547943.
12. Keshavarz P, Yazdanpanah F, Rafiee F, Mizandari M. Lymphadenopathy following COVID-19 vaccination: imaging findings review. Acad Radiol. 2021 Aug;28(8):1058-71. doi: 10.1016/j.acra.2021.04.007. Epub 2021 May 1. PMID: 33985872; PMCID: PMC8088218.
13. Raj S, Ogola G, Han J. COVID-19 vaccine-associated subclinical axillary lymphadenopathy on screening mammogram. Acad Radiol. 2022 Apr;29(4):501-7. doi:
10.1016/j.acra.2021.11.010. Epub 2021 Nov 17. doi: 10.1016/j.acra.2022.03.029. PMID: 34906409; PMCID: PMC8595349.
14. COVID-19 vaccine-related lymphadenopathy may affect breast screening. Reactions Weekly. 2021;1846(1):1. doi: 10.1007/s40278-021-92249-y. Epub 2021 Mar 13. PMCID: PMC7954685.
15. Robinson KA, Maimone S, Gococo-Benore DA, Li Z, Advani PP, Chumsri S. Incidence of axillary adenopathy in breast imaging after COVID-19 vaccination. JAMA Oncol. 2021 Sep 1;7(9):1395-7. doi: 10.1001/jamaoncol.2021.3127. PMID: 34292295; PMCID: PMC8299355.
16. Mahase E. Covid-19: Schedule breast screening before vaccine or 4 to 6 weeks after to avoid false positives, says guidance. BMJ 2021 Mar 3;372:n617. doi: 10.1136/bmj. n617. PMID: 33658188.
17. National Comprehensive Cancer Network. Recommendations of the NCCN Advisory Committee on COVID-19 vaccination and pre-exposure prophylaxis. Version 5.0. 01.04.2022. Available from: https://aonnonline.org/images/ resources/navigation_tools/covid-19/vaccines/nccn_2021_ covid-19_vaccination_guide_v5_2.pdf [Last accessed: 2025 Feb 4].
18. Schiaffino S, Pinker K, Magni V, Cozzi A, Athanasiou A, Baltzer PAT, et al. Axillary lymphadenopathy at the time of COVID-19 vaccination: ten recommendations from the European Society of Breast Imaging (EUSOBI). Insights Imaging. 2021 Aug 20;12(1):119. doi: 10.1186/s13244021-01062-x. PMID: 34417642; PMCID: PMC8378785.
19. Park JY, Lee JY and Yi SY. Axillary lymphadenopathy on ultrasound after COVID-19 vaccination and its influencing factors: a single-center study. J Clinical Med. 2022 Jan
3;11(1):238. doi: 10.3390/jcm11010238. PMID: 35011979; PMCID: PMC8746129.
20. Muzi M, Bucchi L, Caumo F, Deandrea S, Galli V, Gennaro G, et al. Screening mammografico dopo la pandemia: indicazioni ad interim per la riorganizzazione dei programmi GISMa. Available from: www.gisma.it/wp-content/ uploads/2022/04/Gisma_Screening_e_Covid19.pdf [Last accessed: 2025 Feb 11].
21. Squillace L, Pizzi L, Rallo F, Bazzani C, Saguatti G, Mezzetti F. Subsequent attendance in a breast cancer screening program after a false-positive result in the Local Health Authority of Bologna (Italy). Sci Rep. 2021 Apr 20;11(1):8530. doi: 10.1038/s41598-021-87864-x. PMID: 33879804; PMCID: PMC8058078.
22. Garreffa E, Hamad A, O’Sullivan CC, Hazim AZ, York J,
Puri S, et al. Regional lymphadenopathy following COVID19 vaccination: literature review and considerations for patient management in breast cancer care. Eur J Cancer. 2021 Dec;159:38-51. doi: 10.1016/j.ejca.2021.09.033. Epub 2021 Oct 11. PMID: 34731748; PMCID: PMC8502686.
23. StataCorp. Stata Statistical Software: Release 16. StataCorp LP; 2019.
24. Cocco G, Delli Pizzi A, Fabiani S, Cocco N, Boccatonda A, Frisone A, et al. Lymphadenopathy after the anti-COVID-19 vaccine: multiparametric ultrasound findings. Biology (Basel). 2021 Jul 12;10(7):652. doi: 10.3390/biology10070652. PMID: 34356507; PMCID: PMC8301414.
25. Wolfson S, Kim E, Plaunova A, Bukhman R, Sarmiento RD, Samreen N, et al. Axillary adenopathy after COVID-19 vaccine: no reason to delay screening mammogram. Radiology. 2022;303(2):297-9. doi: 10.1148/radiol.213227. Epub 2022 Feb 8. PMID: 35133198; PMCID: PMC8855316.
26. Horvat JV, Sevilimedu V, Becker AS, Perez-Johnston R, Yeh R, Feigin KN. Frequency and outcomes of MRI-detected axillary adenopathy following COVID-19 vaccination. Eur Radiol. 2022 Aug;32(8):5752-8. doi: 10.1007/s00330-022 -08655-0. Epub 2022 Mar 5. PMID: 35247087; PMCID: PMC8897548.
27. Centers for Disease Control and Prevention (CDC). The Moderna COVID-19 vaccine’s local reactions, systemic reactions, adverse events, and serious adverse events. Archived 4/3/2024. Available from: archive.cdc.gov/www_cdc_gov/ vaccines/covid-19/info-by-product/moderna/reactogenicity. html [Last accessed: 2024 Jan 20].
28. Centers for Disease Control and Prevention (CDC). PfizerBioNTech COVID-19 vaccine reactions & adverse events. 2022. Available from: www.cdc.gov/vaccines/covid-19/ info-by-product/pfizer/reactogenicity.html [Last accessed: 2024 Oct 25].
29. Centers for Disease Control and Prevention (CDC). Janssen COVID-19 vaccine reactions & adverse events. 2022. Available from: www.cdc.gov/vaccines/covid-19/info-byproduct/janssen/reactogenicity.html [Last accessed: 2024 Oct 25].
30. Medicines and Healthcare products Regulatory. Agency Information for UK recipients on COVID 19 vaccine AstraZeneca-regulation. Available from: www.gov.uk/ government/publications/regulatory-approval-of-covid19-vaccine-astrazeneca/information-for-uk-recipients-oncovid-19-vaccine-astrazeneca. 2023. [Last accessed: 2024 Jan 20].
31. Agenzia Italiana del Farmaco (AIFA). Rapporto sulla Sorveglianza dei vaccini COVID-19 - Rapporto 9 - Periodo dal 27/12/2020 al 26/09/2021. Available from: www.aifa. gov.it/rapporti-su-sorveglianza-dei-vaccini-covid-19 [Last accessed: 2025 Feb 4].
32. Regione Emilia-Romagna. Screening – Il percorso e i risultati, salute.regione.emilia-romagna.it/screening/ mammografico/i%20risultati. 2023 [Last accessed: 2025 Feb 4].
33. Giordano L, Giorgi D, Frigerio A, Bravetti P, Paci E, Petrella M, et al. Indicatori e standard per la valutazione di processo dei programmi di screening del cancro della mammella [Process indicators and standards for the evaluation of breast cancer screening programmes]. Epidemiol Prev. 2006 MarApr;30(2 Suppl 1):5-9,11-47. Italian. PMID: 16916012.
34. Özütemiz C, Krystosek LA, Church AL, Chauhan A, Ellermann JM, Domingo-Musibay E, et al. Lymphadenopathy
in COVID-19 vaccine recipients: diagnostic dilemma in oncologic patients. Radiology. 2021 Jul;300(1):E296-E300. doi: 10.1148/radiol.2021210275. Epub 2021 Feb 24. PMID: 33625300; PMCID: PMC7909072.
35. Mehta N, Sales RM, Babagbemi K, et al. Unilateral axillary adenopathy in the setting of COVID-19 vaccine. Clin Imaging. 2021 Jul;75:12-5. doi: 10.1016/j. clinimag.2021.01.016. Epub 2021 Jan 19. PMID: 33486146; PMCID: PMC7817408.
36. Granata V, Fusco R, Setola SV, Levy AD, McGrath AL, Drotman M, et al. Lymphadenopathy after BNT162b2 Covid-19 vaccine: preliminary ultrasound findings. Biology. 2021 Mar 11;10(3):214. doi: 10.3390/biology10030214. PMID: 33799618; PMCID: PMC8001230.
37. Aleman RT, Rauch J, Desai J, Chaiban JT. COVID-19 vaccine-associated lymphadenopathy in breast imaging recipients: a review of literature. Cureus. 2022 Jul 14;14(7):e26845. oi: 10.7759/cureus.26845. PMID: 35974844; PMCID: PMC9375123.
38. Istituto Superiore di Sanità (ISS). Vaccini anti COVID-19. 2021. Available from: www.epicentro.iss.it/vaccini/covid-19 [Last accessed: 2025 Feb 11].
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Lorena Squillace, Lorenzo Pizzi, Angela Chierghin, Carmen Bazzani, Gianni Saguatti, Alfredo Tafà, Lorenzo Roti, Francesco Mezzetti (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.